Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar ah6br (< 20) Submitted: 5/10/2010 4:58:12 PM : Outperform Start Price: $2.67 NVAX Score: -67.23

New vaccine technology.

Featured Broker Partners


Advertisement